AgingResearch.NewsJoin free

Phase 2CompletedAge-related condition

Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS

Open Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Ciprofloxacin/Celecoxib Combination in Patients With ALS

Sponsor
NeuroSense Therapeutics Ltd. (Industry)
Enrolment
16 enrolled
Conditions
Amyotrophic Lateral Sclerosis; ALS
Interventions
Fixed dose combination Ciprofloxacin/Celecoxib
Ages
adults, older adults
Registry
NCT04165850

Full record on ClinicalTrials.gov

From the registry

This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital Capacity).

Primary outcomes

  • Number of participants with one or more treatment-emergent adverse events
  • Number of patients who discontinued treatment prematurely
  • Number of patients who discontinued treatment prematurely due to adverse events
  • Number of patients with significant abnormal laboratory values

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered